Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Nov;8(7):2514-2516.
doi: 10.21037/tcr.2019.05.20.

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer

Camille Travert  1   2   3 , Pascale Tomasini  3 , Arnaud Jeanson  3 , Laurent Greillier  3 , Fabrice Barlesi  3
Affiliations
Editorial

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer

Camille Travert et al. Transl Cancer Res. 2019 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.05.20). Dr. Barlesi reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda, outside the submitted work; Dr. GREILLIER reports personal fees and non-financial support from ABBVIE, personal fees and non-financial support from BRISTOL MYERS SQUIBB, personal fees and non-financial support from BOEHRINGER INGELHEIM, personal fees and non-financial support from ASTRA ZENECA, personal fees and non-financial support from ROCHE, personal fees and non-financial support from NOVARTIS, personal fees and non-financial support from MSD, personal fees and non-financial support from PFIZER, personal fees and non-financial support from TAKEDA, outside the submitted work; Dr. Tomasini reports grants, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from Astra-Zeneca, personal fees and non-financial support from BMS, personal fees and non-financial support from Takeda, outside the submitted work; Dr. JEANSON has nothing to disclose; Dr. Travert has nothing to disclose.

Comment on

References

    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819-30. 10.1016/S0140-6736(18)32409-7 - DOI - PubMed
    1. Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017;376:2415-26. 10.1056/NEJMoa1613493 - DOI - PMC - PubMed